3034 results for "Psilocybin"
Engineering artificial biosynthetic pathways for efficient microbial production of psilocybin and psilocin
Metabolic Engineering – November 05, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 01, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
Pharmacological Research – December 29, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Sudden Loss of Consciousness Following Psilocybin Ingestion
American Journal of Psychiatry – December 01, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Divergent effects of ketamine and psilocybin on EEG power spectral density in a mismatch negativity paradigm
Psychopharmacology – November 05, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Calcium activation mechanism of a noncanonical aromatic L-amino acid decarboxylase from psilocybin mushroom Psilocybe cubensis
Communications Biology – February 26, 2026
Summary
PcncAAAD, a unique fungal enzyme, is activated by calcium, unlike its mammalian and plant relatives. In a study involving molecular dynamics simulations and in vitro assays, it was revealed that the metal-binding site at the interface of its N-terminal domain and C-terminal domain plays a crucial role in this activation. Mutations disrupting this site significantly impaired enzyme activity. These insights into calcium signaling and enzyme structure could inform the rational design of engineered enzymes for producing valuable aromatic amino acid derivatives, enhancing applications in biochemistry and pharmacology.
Abstract
PcncAAAD is a noncanonical fungal aromatic L-amino acid decarboxylase (AAAD) featuring a unique appendage C-terminal domain (CTD) and two metal-bin...
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry – October 23, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psychotrophic Compounds from Psilocybin Mushrooms
Springer protocols handbooks/Springer protocols – November 22, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
Therapeutic Advances in Psychopharmacology – December 01, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports
Psychedelics – November 20, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil
International Journal of Drug Policy – February 18, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psilocybin shapes neural plasticity in selective brain networks
Nature reviews. Neuroscience – January 06, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Psilocybin for Treatment-Resistant OCD: A Randomised Controlled Trial
SSRN Electronic Journal – January 01, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis
Pharmacological Reports – January 20, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Regarding “The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses”
Translational Psychiatry – January 31, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Rebuttal to “Questioning the recovery of dissociated traumatic memories under psilocybin”
Journal of Eating Disorders – February 17, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
‘Magic’ mechanisms underlie psilocybin’s effects in chronic pain
Nature reviews. Neuroscience – November 11, 2025
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA).
Professional Psychology Research and Practice – February 01, 2026
Summary
No Summary
Abstract
Abstract not available from OpenAlex
Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice
ACS Pharmacology & Translational Science – March 10, 2023
Summary
Beyond the expected 5-HT2A receptor, new tryptamine psychedelics influence behavior through complex pharmacology, targeting multiple serotonin receptors, including 5-HT1A. Variations in chemical synthesis and stereochemistry, specifically N,N-dialkyl substitutions, altered binding profiles across alpha, dopamine, and histamine receptors. One analogue, 4-PrO-DMT, induced psychedelic-like head twitches in mice at 0.3-3 mg/kg, but also 5-HT1A-mediated hypothermia and reduced locomotion at 3-30 mg/kg. This suggests 5-HT1A activity can attenuate 5-HT2A-mediated effects, crucial for understanding neurotransmitter receptor influence on behavior in drug studies.
Abstract
Analogues of 4-phosphoryloxy-N,N-dimethyltryptamine (psilocybin) are being sold on recreational drug markets and developed as potential medications...
Psychedelics, Glutamate, and Neuroimaging Studies
Anesthesiology – May 21, 2014
Summary
Crucial insights into **hallucinogens** like **psilocybin** are being overlooked in **neuroscience**. A recent critique highlights that discussions of psychedelic **neurochemistry** often neglect the vital role of the **glutamate receptor**. Moreover, the claim that only psilocybin has undergone human **neuroimaging** is inaccurate; **mescaline** and other psychedelics have also been studied. These omissions in **pharmacology** and **medicine** impede a comprehensive understanding of **Psychedelics and Drug Studies**, impacting our grasp of **psychology** and **Neurotransmitter Receptor Influence on Behavior**.
Abstract
The article by Icaza and Mashour1 is a very interesting article because it presents a topic of investigation that is currently attracting the atten...
Development and validation of an analytical method for the determination of select 4-position ring-substituted tryptamines in plasma by liquid chromatography–tandem mass spectrometry
Journal of Analytical Toxicology – May 26, 2025
Summary
Concentrations of the psychedelic **tryptamine** **psilocin** reached 32.7 ng/mL in male rat plasma after administering its prodrug. A sensitive **liquid chromatography–tandem mass spectrometry** method, utilizing **electrospray ionization** and **selected reaction monitoring**, now precisely quantifies **psilocybin** and five other related **tryptamines** and their **metabolites**. This advanced **chemistry** technique, vital for **Psychedelics and Drug Studies** and **Forensic Toxicology and Drug Analysis**, demonstrated linearity from 0.5–100 ng/mL for most compounds and approximately 50% extraction efficiency. It offers robust detection of these **alkaloids**.
Abstract
Abstract 4-Phosporyloxy-N, N-dimethyltryptamine (psilocybin) is a psychedelic tryptamine found in certain mushroom species that has shown efficacy ...
Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions
Frontiers in Psychology – July 25, 2017
Summary
A compelling finding in applied psychology reveals that music therapy significantly shapes mystical experiences during psilocybin sessions. Ten psychotherapists and staff, experienced in clinical psychology and Psychedelics and Drug Studies, identified 22 musical examples optimally supporting peak effects. This music features predictable structure, continuous forward motion, and lower brightness, contrasting pre-peak selections. This specific guidance for music selection aids future psychedelic research, enhancing therapeutic outcomes and understanding the cognitive psychology of altered states.
Abstract
Psilocybin is a classic (serotonergic) hallucinogen ("psychedelic" drug) that may occasion mystical experiences (characterized by a profound feelin...
Psychedelic Identity Shift: A Critical Approach to Set And Setting
Kennedy Institute of Ethics journal – December 01, 2022
Summary
Psilocybin-assisted smoking cessation profoundly reshapes a person's **identity**, offering powerful **empowerment**. A **psychotherapist** using specific frameworks, or "set," alongside **psilocybin** can facilitate rapid shifts in self-perception, as shown in a pilot **smoking cessation** study. This **narrative** analysis from **Psychedelics and Drug Studies** highlights how structured support interacts with the substance. As **psychedelics** become **mainstream**, respecting patient **autonomy** and understanding this **psychology** of change is crucial for ethical practice.
Abstract
While the literature on psychedelic medicine emphasizes the importance of set and setting alongside the quality of subjective drug effects for ther...
New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy
Frontiers in Psychiatry – September 10, 2021
Summary
Despite a 2021 Phase II study showing no primary outcome advantage for psilocybin-assisted therapy over escitalopram, secondary measures favored psilocybin for depression. This sparked critical discussions in Psychiatry, Psychology, and therapeutic fields like Psychoanalysis, questioning trial methodology for Psychedelics and Drug Studies. Psychotherapists in Medicine suggest the "bubble" of enthusiasm might be bursting. A nuanced view acknowledges both potential and pitfalls for this mental healthcare frontier, considering neurotransmitter receptor influence on behavior and chemical synthesis of alkaloids.
Abstract
The publication in April 2021 of the Imperial College London Phase II study investigating \nthe efficacy of psilocybin-assisted therapy vs. esc...
The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions
Frontiers in Pharmacology – February 21, 2018
Summary
Patients receiving the hallucinogen psilocybin for alcohol dependence offer insights into its therapeutic potential. Qualitative research analyzed 17 debriefing sessions, where individuals described how this alkaloid's acute effects contributed to reduced drinking. This work in clinical psychology and psychiatry, part of broader psychedelics and drug studies, illuminates change processes. A psychotherapist guides these sessions, informing medicine for a wider population. Understanding psilocybin's biochemistry, informed by chemical synthesis and biochemical analysis, is key.
Abstract
Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol depen...
Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts
Journal of Psychopharmacology – June 25, 2018
Summary
Psilocybin shows promise for addiction treatment, particularly in smoking cessation. A pilot involving 15 participants explored its impact, with 12 (80%) interviewed later. Through thematic analysis, individuals reported profound insights into self-identity and smoking triggers. Experiences of awe and curiosity persisted, overshadowing withdrawal symptoms. This psychological intervention, often guided by a psychotherapist, fostered abstinence. Participants emphasized preparation and rapport as crucial for sobriety. This qualitative research highlights psilocybin's role in clinical psychology and medicine, demonstrating its potential for challenging addiction within psychedelics and drug studies.
Abstract
Background: Recent pilot trials suggest feasibility and potential efficacy of psychedelic-facilitated addiction treatment interventions. Fifteen pa...
Group format psychedelic-assisted therapy interventions: Observations and impressions from the HOPE trial
Journal of Psychedelic Studies – January 18, 2023
Summary
Group psychotherapy offers a promising path to scale psilocybin as a psychological intervention for distress and anxiety in medical illness. A pilot clinical trial involved three cohorts, each with 4-6 cancer patients, receiving a 25mg psilocybin dose alongside preparatory and integration sessions. Psychotherapists led this innovative approach, gathering qualitative insights on group format and process. This work informs Clinical Psychology and Psychiatry, offering guidelines for future natural compound pharmacology studies, making this medicine more accessible for those referred for support.
Abstract
Abstract Background Psilocybin-assisted psychotherapy has demonstrated significant promise as a treatment for depression, anxiety, and existential ...
Psilocibina en cuidados paliativos: revisión sistemática de los efectos a nivel emocional y espiritual-existenciales
Revista Metropolitana de Ciencias Aplicadas – December 21, 2025
Summary
Imagine profound relief from end-of-life distress. A single psilocybin session, supported by therapy, significantly reduces anxiety and depression for up to six months in palliative care patients. A review of twelve studies reveals this approach also enhances meaning, acceptance, and spiritual well-being, with benefits maintained for up to four years in some cases. Adverse events were mild and temporary, like nausea or headache. Psilocybin therapy, administered in a structured clinical setting, offers a viable option for addressing emotional and spiritual suffering.
Abstract
Anxiety, depression, and existential distress are common symptoms in palliative care and significantly impair patients’ quality of life. Psilocybin...
Empirically validated theoretical analysis of visual-spatial perception under change of nervous system arousal
Frontiers in Computational Neuroscience – May 12, 2023
Summary
A new neuroscience model accurately predicts how psychedelics and other drugs alter visual perception. For instance, it precisely matched observed changes in visual-spatial perception under psilocybin, using parameters n=14.8 and k=1.39. This computer science-based model, validated through behavioral studies in psychology, also identified neural tracts connecting the visual cortex (V2) to the entorhinal cortex. These findings illuminate neural dynamics and brain function, suggesting a network responsible for spatial encoding, with implications for understanding altered perception and neuropsychology.
Abstract
Introduction Visual-spatial perception is a process for extracting the spatial relationship between objects in the environment. The changes in visu...
The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges
Risk Management and Healthcare Policy – March 01, 2021
Summary
Psilocybin and other hallucinogens show promise in psychiatry, offering rapid, enduring relief for severe mental disorders using single or few doses. Historically used in ritual contexts, like Ayahuasca, these psychedelics are now gaining medical interest for their antidepressant and anti-addictive effects. Pharmacology reveals their action on 5-HT2A receptors. Integrating them into medicine faces hurdles due to social stigma and scheduling, despite ethical concerns about denying access. Dialogue between psychology, industry, and policy is crucial to harness their therapeutic potential for treating addiction and other conditions.
Abstract
Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT2A receptors as their main mechanis...
Methodological Issues of Human Experimental Research with Hallucinogens
Pharmacopsychiatry – July 01, 1998
Summary
Psilocybin, a potent hallucinogen, uniquely influences cognitive psychology, demonstrating time-dependent effects on semantic priming. This reveals a crucial link between neurobiological alterations and psychopathological conditions, offering insights into acute psychotic states. Such psychedelics and drug studies are vital for understanding neurotransmitter receptor influence on behavior, advancing neuroscience. Rigorous methodology, including subject selection and control groups, is paramount. While specific data like sample sizes or percentages were not provided, these findings underscore the power of experimental psychology in this domain.
Abstract
Human experimental research with hallucinogenic drugs is potentially able to identify linking variables between the psycho(patho)logical conditions...
Psychedelic-Assisted Psychotherapy for Post-Traumatic Stress Disorder, Anxiety Disorders, Mood Disorders, or Substance Use Disorders
Canadian Journal of Health Technologies – June 24, 2021
Summary
Psychedelics show significant potential in medicine, improving mental health symptoms with no serious adverse events. One randomized controlled trial found psilocybin-assisted psychotherapy efficacious for mood disorders like depression. Across two systematic reviews and three randomized controlled trials, various hallucinogens, including MDMA, combined with psychotherapist support, demonstrated clinical effectiveness for conditions like anxiety. This growing area in clinical psychology and psychiatry, part of broader drug studies, explores how these compounds, often from chemical synthesis, influence behavior. Sample sizes were typically under 20, warranting further investigation.
Abstract

 Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations o...
Et psykoanalytisk og et postmoderne perspektiv på selv/egoopløsning i en psykedelisk kontekst
OpenAlex – January 04, 2023
Summary
A compelling finding from empirical research on self-dissolution during psilocybin-assisted psychotherapy is a profound feeling of connection. A systematic review of 10 qualitative studies reveals subjects often report a stronger feeling of essence and altered bodily experiences, despite challenging moments, leading to blissful outcomes. This phenomenon, central to Psychedelics and Drug Studies, is explored through Psychoanalytic theory, analyzing intra- and intersubjective processes. Another psychological perspective examines the influence of the therapeutic context on the subject's experience, providing insights for Mental Health and Psychiatry and Psychotherapy Techniques and Applications, enriching our understanding of the human psyche.
Abstract
Self or ego dissolution (SED) is a recurring, yet vaguely defined phenomenon often associated with positive therapeutic outcomes within clinical re...
Neural mechanisms of psychedelic visual imagery
OpenAlex – September 09, 2022
Summary
Psilocybin, a potent hallucinogen, profoundly alters visual perception. Using functional magnetic resonance imaging (fMRI) on 24 adults, Neuroscience and Psychology investigations reveal how this psychedelic drug impacts the visual cortex. Under psilocybin, enhanced top-down feedback from higher visual areas to the early visual cortex appears to drive vivid, eyes-closed visual imagery. This suggests psilocybin reduces external stimulus impact, allowing internal cognitive processes to dominate perception. These insights from Psychedelics and Drug Studies advance our understanding of visual perception and the brain's mechanisms for creating internal visual experiences.
Abstract
Abstract Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence sugg...
Neural mechanisms of psychedelic visual imagery.
Molecular psychiatry – April 01, 2025
Summary
Brain scans reveal how psychedelic mushrooms create vivid mental imagery. When people see colorful visions with closed eyes during a psilocybin experience, it's because the brain's visual areas become more self-regulating while allowing stronger feedback from higher brain regions. This unique pattern helps explain the rich visual experiences commonly reported during psychedelic states.
Abstract
Visual alterations under classic psychedelics can include rich phenomenological accounts of eyes-closed imagery. Preclinical evidence suggests agon...
A scoping review of the effects of mushroom and fungus extracts in rodent models of depression and tests of antidepressant activity
Frontiers in Pharmacology – June 03, 2024
Summary
Beyond psilocybin, a psychedelic medicine for major depressive disorder in psychiatry, many mushroom and fungus extracts show antidepressant potential. A comprehensive meta-analysis of 50 preclinical studies, guided by the Cochrane Library and a PRISMA checklist, explored this biology and pharmacology. Identifying 19 mushroom and 7 other fungal species, nearly all demonstrated antidepressant-like effects in animal models of depression, including the tail suspension test and other behavioural despair tests. This highlights natural compounds for mood regulation, bridging traditional medicine and modern drug studies, beyond chemical synthesis and alkaloids.
Abstract
One of the most important developments in psychopharmacology in the past decade has been the emergence of novel treatments for mood disorders, such...
Critique of the Royal Australian and New Zealand College of Psychiatrists Psychedelic Therapy Clinical Memorandum, Dated May 2020
Journal of Medical and Health Studies – December 31, 2021
Summary
Remarkably, no scientific evidence from the last 70 years links controlled psilocybin or MDMA-assisted therapies to mental illness. A review of the Royal Australian and New Zealand College of Psychiatrists' 2020 Clinical Memorandum found these psychedelics are safe, non-toxic medicine when clinically administered, contrary to their Psychiatry stance. The Memorandum's position on these hallucinogens, often discussed in Psychedelics and Drug Studies, relies on outdated information. Accurate discourse, including insights from Forensic Toxicology and Drug Analysis and Cannabis and Cannabinoid Research, is crucial to prevent self-medication.
Abstract
Objective: The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has positioned itself against medically controlled patient access...
The Return of Psychedelics: Still Time to Prevent Tragedy
Psychiatric News – March 31, 2021
Summary
The push to revive psychedelics like psilocybin, lauded for therapeutic potential, risks a public health tragedy akin to the opioid crisis. Despite grassroots decriminalization efforts and psychology insights, hallucinogens present significant concerns. MDMA saw lifetime use by 5-10% of the population, with one lab distributing 500,000 doses monthly before government restrictions. Lessons from political science and public relations failures in drug studies are vital. Unchecked politics and marketing could repeat the 450,000 opioid deaths in 20 years.
Abstract
Back to table of contents Previous article Next article ViewpointsFull AccessThe Return of Psychedelics: Still Time to Prevent TragedyStanley N. Ca...
Prolonged hallucinogenic effects following Psilocybe cubensis ingestion: Case report
The poison. – June 30, 2025
Summary
Weeks after Psilocybin ingestion, a powerful hallucinogen, one documented case experienced prolonged perceptual disturbances and flashbacks, necessitating psychopharmacological intervention. This highlights potential neuropsychiatric symptoms. Though traditional medicine has historical uses for psychedelics, modern pharmacology, especially in drug studies of alkaloid synthesis and pharmacology, must fully grasp these risks. Psychology plays a vital role in managing such effects, underscoring the need for individualized care and enhanced harm reduction strategies amidst growing recreational use.
Abstract
Psilocybe cubensis is a widely used psilocybin-containing mushroom with well-documented acute psychoactive effects. We report a case of prolonged p...
Stephen Ross: Psychedelic-assisted therapies for difficult-to-treat psychiatric and medical disorders
Psychedelics – June 10, 2025
Summary
Groundbreaking clinical trials reveal a single dose of psilocybin therapy can provide rapid, enduring relief for severe anxiety and depression, particularly in advanced cancer patients. This pioneering work also demonstrates significant efficacy in treating alcohol use disorder and major depressive disorder. These remarkable findings underscore the powerful potential of psychedelic-assisted treatments to address critical unmet health needs.
Abstract
Professor Stephen Ross is a prominent faculty member in the Departments of Psychiatry and Child and Adolescent Psychiatry at the New York Universit...
Corrigendum to “Decreases in Suicidality Following Psychedelic Therapy
The Journal of Clinical Psychiatry – May 09, 2022
Summary
Two suicidality-related events occurred within psychedelic trials, despite not being directly attributed to the compounds. One individual died by suicide 11 days after a 1 mg/70 kg psilocybin dose. Another attempted suicide two months post-treatment with 21-25.2mg/70 kg psilocybin, following other drug use and personal tragedy. These cases highlight the importance for psychotherapists in Psychology and Psychedelics and Drug Studies to closely monitor patients, recognizing how chemical synthesis of alkaloids like psilocybin can influence neurotransmitter receptors and behavior.
Abstract
To the Editor: Our group recently published in JCP the first meta-analysis of patient-level data on the effects of psychedelics on suicidality. 1 W...
The effect of casing and gypsum on the yield and psychoactive tryptamine content of Psilocybe cubensis (Earle) Singer.
Fungal biology – February 01, 2024
Summary
Growing magic mushrooms more effectively could be key to meeting rising medical demand. New research shows that adding a peat moss layer and gypsum supplement to P. cubensis cultivation dramatically improves yields. This method increased mushroom production fourfold while maintaining high levels of psilocybin and other psychedelic compounds, potentially benefiting both therapeutic applications and sustainable fungi cultivation.
Abstract
Psychedelic fungi have experienced a surge in interest in recent years. Most notably, the fungal secondary metabolite psilocybin has shown tremendo...
Neurotropic Effect of Extracts from the Hallucinogenic Mushroom Psilocybe cubensis (Earle) Sing. (Agaricomycetideae). In Vitro Studies
International journal of medicinal mushrooms – January 01, 2000
Summary
Psilocybin, a potent hallucinogen, profoundly inhibits brain activity, revealing key insights for Psychedelics and Drug Studies. Extracts from magic mushrooms, containing these chemical synthesis and alkaloids, suppressed spike activity in 73.5% to 81% of 50 rat hippocampal formation neurons. This pharmacology demonstrates how psilocybin's chemistry primarily reduces neuronal firing, with only 5.9% showing excitation. Blocking serotonin receptors reversed these effects in half of the units, underscoring the Neurotransmitter Receptor Influence on Behavior.
Abstract
The neurotropic effect of Psilocybe cubensis (Earle) Sing, dried biomass and fruiting bodies containing the indole hallucinogens psilocybin and psi...
Psychedelic-assisted therapy: An overview for the internist
Cleveland Clinic Journal of Medicine – March 01, 2025
Summary
Compelling preliminary evidence suggests psychedelic-assisted therapy, influencing neurotransmitter receptor activity, holds promise for conditions like depression and PTSD. These Psychedelics and Drug Studies, involving compounds like MDMA and psilocybin, have earned breakthrough therapy designations. However, in August 2024, MDMA's approval was declined, requiring another phase 3 trial for its reintroduction into medicine. This rigorous process highlights the careful evaluation. Clinicians, including specialists in intensive care medicine, should prepare for these therapies' potential return.
Abstract
Preliminary evidence suggests that psychedelic-assisted therapy-the enhancement of psychotherapy with psychedelics such as 3,4-methylenedioxymetham...
Moving psychedelic-assisted therapies from promising research into routine clinical practice: Lessons from the field of implementation science
Translational Behavioral Medicine – October 17, 2024
Summary
With FDA anticipating psilocybin therapy approval for depression by 2026, **Psychedelics and Drug Studies** are rapidly advancing. Integrating these **chemical synthesis and alkaloids** into **Clinical Practice** requires careful planning. **Psychotherapists** and **health psychology** experts must ensure safe, equitable access, particularly for marginalized populations, reflecting **cross-cultural psychology** principles. Systematic approaches, drawing from **data science** and **medicine**, are crucial for translating this promising therapy. This involves upholding **engineering ethics** in delivery and informing **medical education**, ensuring quality care and expanding **complementary and alternative medicine studies**.
Abstract
Abstract Psychedelics (e.g., 3,4-Methylenedioxymethamphetamine [MDMA], lysergic acid diethylamide [LSD], psilocybin) are molecules that have the po...
Assessing the Attitudes of Dutch Mental Health Care Professionals Toward Psychedelic-Assisted Psychotherapy: A Cross-Sectional Exploratory Study
Journal of Psychoactive Drugs – June 23, 2025
Summary
Dutch mental health professionals largely embrace psychedelic-assisted psychotherapy, a promising development in mental health care. A cross-sectional study of 198 clinicians revealed positive attitudes toward treatments using compounds like MDMA and psilocybin. This exploratory research in psychology found attitudes correlated with prior personal use of these natural compound pharmacology studies. Psychotherapists believe psychiatrists and clinical psychologists are ideal administrators, preferring specialized hospital settings within medicine. While supporting psychedelics and drug studies, including chemical synthesis and alkaloids, concerns persist about connecting with patients during altered states.
Abstract
Psychedelic-assisted psychotherapy (PAP) constitutes a novel treatment paradigm in mental health care practice that is currently being evaluated fo...
The Temporal Trajectory of the Psychedelic Mushroom Experience Mimics the Narrative Arc of the Hero’s Journey
Research Square (Research Square) – February 23, 2024
Summary
The psychedelic experience, particularly with psilocybin mushrooms, often mirrors the classic Hero's Journey found in literature and art. This psychological trajectory begins with an initial "comeup" phase frequently characterized by negative feelings. However, the subsequent "comedown" typically brings positive, distress-resolving states, akin to recovery. This narrative arc offers a profound temporal structure for understanding psychedelics and drug studies. Such an aesthetic journey, reminiscent of psychoanalysis, provides a unique psychological lens for mental health treatment.
Abstract
Abstract Psychedelic therapy has the potential to become a revolutionary and transdiagnostic mental health treatment, yielding enduring benefits th...
The Watts Connectedness Scale: a new scale for measuring a sense of connectedness to self, others, and world
Psychopharmacology – August 08, 2022
Summary
Psychedelic experiences significantly boost feelings of connectedness, a vital psychological construct. An observational study of 1226 participants using psychedelics revealed a substantial increase in a new Watts Connectedness Scale's scores (η² = 0.339), which demonstrated strong construct validity. This scale measures connection to self, others, and the wider world. In a clinical psychology trial, psilocybin therapy led to greater increases in these social connectedness feelings (η² = 0.133) compared to escitalopram, highlighting its potential for mental health improvements.
Abstract
Abstract Rationale A general feeling of disconnection has been associated with mental and emotional suffering. Improvements to a sense of connected...
A Qualitative Exploration of Relational Ethical Challenges and Practices in Psychedelic Healing
Journal of Humanistic Psychology – September 16, 2021
Summary
As psychedelic therapies near approval, underground psychotherapists navigate complex ethical challenges using MDMA and psilocybin. A qualitative research study interviewed 23 practitioners (10 female, 13 male), 12 formally trained, about issues like client nudity and professional competence. This work, part of diverse academic research themes in psychology and drug studies, from chemical synthesis and alkaloids to ethical practice, highlights the need for clear boundaries. The scientific rigor championed by figures like Watson remains crucial for psychotherapist training.
Abstract
As both 3,4-methylenedioxymethamphetamine (MDMA)- and psilocybin-assisted psychedelic psychotherapy near U.S. Food and Drug Administration (FDA) ap...
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms
Journal of Psychopharmacology – April 07, 2022
Summary
"Magic mushrooms" containing psilocybin, a psychoactive alkaloid, rarely cause serious adverse effects necessitating a medical emergency. From 9233 past-year users globally, only 19 (0.2%) sought emergency medical treatment, a per-event risk of 0.06%. Young age was the sole predictor. Most incidents involved psychological symptoms—anxiety/panic—relevant to Psychiatry, often due to poor mindset. All but one returned to normality within 24 hours. These Psychedelics and Drug Studies confirm their safety in Medicine and Complementary and Alternative Medicine, showing severe physiological effects requiring Anesthesia are exceedingly rare.
Abstract
Background: Psilocybin-containing mushrooms are used for recreational, spiritual, self-development and therapeutic purposes. However, physiological...
Microdosing psychedelics: Subjective benefits and challenges, substance testing behavior, and the relevance of intention
Journal of Psychopharmacology – October 08, 2020
Summary
A survey of 6753 individuals reveals that reported benefits of Psilocybin and Lysergic acid diethylamide MicroDose practices overwhelmingly surpass challenges. Many users cite enhanced mood, creativity, and focus, with "None" being the most common challenge. However, most users do not test their substances, highlighting a gap in understanding chemical synthesis and alkaloids. Interestingly, an approach-intention in this Psychology-focused use of Hallucinogen substances predicted fewer benefits, hinting at potential Nocebo Effect mechanisms or complex Neurotransmitter Receptor Influence on Behavior. Future Pharmacology and Clinical psychology studies need rigorous Placebo-controlled designs for these Psychedelics and Drug Studies.
Abstract
Background: Microdosing psychedelics is the practice of taking small, sub-hallucinogenic doses of lysergic acid diethylamide or psilocybin-containi...
Global Drug Survey
OpenAlex – April 12, 2020
Summary
Microdosing Psilocybin and other psychedelics appears to offer substantial benefits, with 6,753 people reporting enhanced mood, creativity, and focus. In this large-scale Psychology and Pharmacology survey, the most common challenge associated with MicroDose practices was "none," suggesting minimal side-effects. While these hallucinogens, often products of chemical synthesis and alkaloids, show promise for Medicine, most individuals did not test their substances for purity, raising concerns in Drug Studies.
Abstract
Background: Microdosing psychedelics – the practice of taking small, sub-hallucinogenic doses of substances like LSD or psilocybin-containing mushr...
Conducting Qualitative Research With Psychedelic Psychopharmacologists: Challenges of Co-Production in an Era of Interdisciplinarity
OpenAlex – January 01, 2017
Summary
Psilocybin, a psychoactive alkaloid, showed very promising outcomes for long-term cigarette smokers in a 2013-2015 clinical trial. Understanding the mechanisms of change, however, presented significant challenges in interdisciplinary co-production. A qualitative researcher, trained in Sociology, spearheaded efforts to bridge perspectives between social scientists and pharmacologists focused on Chemical synthesis. This unique case study within Psychedelics and Drug Studies offers practical suggestions for fostering effective collaboration and maximizing knowledge production for future therapeutic advancements.
Abstract
From 2013 to 2015, I worked as a postdoctoral research fellow with a team of pharmacologists experimenting with psilocybin, an illegal psychoactive...
Is MDD the right target for early-stage psychedelic-assisted therapy trials?
Journal of Psychedelic Studies – September 15, 2021
Summary
Early clinical trials suggest Major Depressive Disorder (MDD) may be an unsuitable target for initial Psychedelics and Drug Studies. The abstract argues MDD's broad definition complicates finding reliable signals for any psychological intervention, like psilocybin-assisted therapy versus escitalopram. Current psychiatric rating scales, such as QIDS, inadequately capture crucial quality of life (healthcare) aspects, vital for assessing these interventions. Moreover, the acceptance fostered by psilocybin, guided by a psychotherapist, can diverge from conventional symptom reduction goals in clinical psychology, making MDD a non-ideal focus for these randomized controlled trials.
Abstract
Abstract The recently published Imperial College study of a Phase II, double-blind, randomized, controlled trial comparing psilocybin-assisted ther...
Acute Kidney Failure and Myocarditis Triggered by Magic Mushroom Toxicity in a Patient With Prior Cocaine Exposure
Cureus – November 12, 2025
Summary
Magic mushroom poisoning can lead to severe acute kidney injury (AKI) and ischemic acute tubular necrosis, as evidenced by a case involving a middle-aged man with a history of cocaine use. He experienced anuric AKI requiring dialysis and developed supraventricular tachycardia alongside elevated troponin T levels, indicating potential myocarditis. Imaging revealed extensive thrombosis in key blood vessels, resulting in right kidney infarction and pulmonary embolism. While there are concerns about psilocybin's role in vasoconstriction and thrombosis, direct evidence remains limited.
Abstract
Magic mushroom poisoning can be associated with acute kidney injury (AKI), primarily due to ischemic acute tubular necrosis (ATN). Additionally, th...
A qualitative analysis of the psychedelic mushroom come-up and come-down.
Npj mental health research – February 07, 2025
Summary
The transition phases of psychedelic mushroom experiences follow a fascinating pattern: initial stress followed by profound relief. Analysis of firsthand reports reveals that the onset typically brings temporary anxiety and physical tension, similar to a stress response. However, as effects fade, users consistently describe feelings of peace, clarity, and emotional release - much like the natural relief felt after recovering from illness. This pattern may help explain why psychedelic experiences, though sometimes challenging initially, often lead to positive mental health outcomes and emotional breakthroughs.
Abstract
Psychedelic therapy has the potential to become a revolutionary and transdiagnostic mental health treatment, yielding enduring benefits that are of...
RE104: Synthesis and Activity of a Novel Serotonergic Psychedelic Prodrug of 4-Hydroxy-N,N-diisopropyltryptamine
ACS Chemical Neuroscience – May 17, 2024
Summary
A single 1 mg/kg dose of the novel prodrug RE104 significantly reduced immobility in rats for a week, highlighting its antidepressant potential. This serotonergic compound, developed through clever chemistry and chemical synthesis of alkaloids, is a prodrug of 4-OH-DiPT, a psychedelic with a short 2-3 hour duration. Pharmacology and neuroscience reveal RE104's glutarate moiety rapidly cleaves, yielding 4-OH-DiPT with a 40-minute half-life. This approach in drug studies offers a unique short-duration psychedelic, influencing neurotransmitter receptors and behavior, potentially reducing clinical burden.
Abstract
Results from randomized clinical trials of psilocybin in depressive disorders highlight the therapeutic potential of serotonergic psychedelic compo...
The Intersection of Mental Health and Sexual and Gender Minority Identities for Older Adults Living with Human Immunodeficiency Virus: A Narrative Review.
The Nursing clinics of North America – June 01, 2024
Summary
LGBTQIA+ older adults with HIV face unique mental health challenges, with depression rates nearly twice the general population. Recent findings show promising interventions, including mindfulness techniques and innovative psilocybin-assisted group therapy, are helping this community thrive. Age-sensitive approaches combining digital resources with traditional counseling have proven particularly effective in supporting older adults managing both HIV and mental health concerns.
Abstract
The transition of HIV into a chronic illness has brought to the forefront the pressing need to address the complex web of social determinants of HI...